Puma Biotechnology | PBYI - Operating Expenses


Puma Biotechnology reported $49.26M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Exelixis USD 362.75M 21.35M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
MacroGenics USD 53.32M 13.68M Dec/2025
Moderna USD 1.78B 242M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Takeda JPY 1.02T 400.98B Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026